PDF herunterladen
Semin Liver Dis 2002; 22(2): 145-156
DOI: 10.1055/s-2002-30101
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver

Dominique Larrey
  • Service d'hépato-gastroenterologie et transplantation, Hôpital Saint Eloi, Montpellier, France
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Mai 2002 (online)

    Lizenzen und Reprints

ABSTRACT

Adverse drug reactions affecting the liver represent an important challenge for safety in drug development. Drugs can reproduce practically the whole spectrum of liver diseases, but acute hepatitis is the most common syndrome. Drug hepatotoxicity is one of the most common causes of fulminant hepatitis. Most hepatic drug reactions occur in only a small proportion of individuals, making them difficult to detect at the time of drug development. Liver injury is principally recognized on the basis of spontaneous reports within the first 2 years of marketing a new drug. The prevalence of drug hepatotoxicity is poorly documented by a small number of retrospective studies. Despite the development of international analytical methods to allow standardized evaluation, the diagnosis remains indeterminate in many cases. Acquired and genetic factors influence the individual susceptibility to drug hepatotoxicity. Important directions for the future include prospective studies of the incidence of hepatic adverse drug reactions, finding specific markers that augment or replace causality assessment, and further elucidating the role of the genetic and environmental factors that contribute to individual susceptibility.

KEYWORDS

Adverse drug reactions - liver - drug hepatotoxicity - drug safety - epidemiology - hepatitis - individual susceptibility pharmacogenetics

REFERENCES

  • 1 Watkins P B, Whitcomb R W. Hepatic dysfunction associated with troglitazone.  N Engl J Med . 1998;  13 916-917
    PubMedGoogle Scholar
  • 2 Lee W M. Assessing causality in drug-induced liver injury.  J Hepatol . 2000;  33 1003-1005
    CrossrefPubMedGoogle Scholar
  • 3 Biour M, Poupon R, Grangé J D, Chazouilleres O. Hépatotoxicité des médicaments.  Gastroenterol Clin Biol . 2000;  11 1052-1091
    PubMedGoogle Scholar
  • 4 Stricker B H C H. Drug-Induced Hepatic Injury, 2nd ed. Amsterdam: Elsevier; 1992
  • 5 Farrell O C. Drug-Induced Liver Disease.  London: Churchill Livingstone; 1994
    Google Scholar
  • 6 Pessayre O, Larrey D, Biour M. Drug-induced liver injury. In: Bircher J, Benhamou JP, McIntyre N, et al, eds. Oxford Textbook of Clinical Hepatology, 2nd ed, vol 2 Oxford: Oxford University Press 1999: 1261-1315
    Google Scholar
  • 7 Zimmerman H J. The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999 . 
    Google Scholar
  • 8 Larrey D. Drug-induced liver diseases.  J Hepatol . 2000;  32 77-88
    PubMedGoogle Scholar
  • 9 Negro F, Mondardini A, Palmas E. Hepatotoxicity of saccharin.  N EngI J Med . 1994;  331 134-135
    PubMedGoogle Scholar
  • 10 Larrey D. Hepatotoxicity of herbal medicines.  J Hepatol . 1997;  26(Suppl 1) 47-51
    CrossrefPubMedGoogle Scholar
  • 11 Schuppan D, Jia J D, Brinkhaus B, Hahn E G. Herbal products for liver diseases: a therapeutic challenge for the new millennium.  Hepatology . 1999;  30 1099-1104
    CrossrefPubMedGoogle Scholar
  • 12 Seeff L B, Lindsay K L, Bacon B R. Complementary and alternative medicine in chronic liver disease.  Hepatology . 2001;  34 595-603
    CrossrefPubMedGoogle Scholar
  • 13 Watkins P B, Zimmerman H J, Knapp M J. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.  JAMA . 1994;  271 992-998
    CrossrefPubMedGoogle Scholar
  • 14 Hammel F, Larrey D, Bernau J. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease.  J Clin Gastroenterol . 1990;  12 329-331
    CrossrefPubMedGoogle Scholar
  • 15 Larrey D. Hépatites médicamenteuses: aspects épidémiologiques, cliniques, diagnostiques, et physiopathologiques en 1995.  Rev Med Interne . 1995;  16 752-758
    PubMedGoogle Scholar
  • 16 Jean-Pastor M J, Jouglard J. Bilan des accidents hépatiques médicamenteux recueillis par la pharmacovigilance française.  Therapie . 1984;  39 453-500
    PubMedGoogle Scholar
  • 17 Dossing M, Andreasen B P. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish board of adverse reaction to drugs.  Scand J Gastroenterol . 1982;  17 205-211
    PubMedGoogle Scholar
  • 18 Bernuau J, Benhamou J P. Fulminant and subfulminant liver failure. In: Bircher J, Benhamou JR, McIntyre N, et al, eds. Oxford Textbook of Clinical Hepatology, 2nd ed, vol 2 Oxford: Oxford University Press 1999: 1341-1372
    Google Scholar
  • 19 Takahashi Y, Okuda K. Fulminant hepatitis in Japan: etiology and prognostic prediction.  Chin J Gastroenterol . 1993;  10 337-350
    PubMedGoogle Scholar
  • 20 Criteria of drug-inducedCriteria of drug-induced liver disorders. Report of an internationa Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol . 1990;  11 272-276
    PubMed
  • 21 Lucena I, Camargo R, Andrade J. Comparison of two clinical scales for causality assessment in hepatotoxicity.  Hepatology . 2001;  33 123-130
    CrossrefPubMedGoogle Scholar
  • 22 Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity.  Hepatology . 2001;  33 308-309
    CrossrefPubMedGoogle Scholar
  • 23 Bissell D M, Gores G J, Laskin D L, Hoofnagle J H. Drug-induced liver injury: mechanism test systems.  Hepatology . 2001;  33 1009-1013
    CrossrefPubMedGoogle Scholar
  • 24 Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.  J Clin Epidemiol . 1993;  46 1331-1336
    CrossrefPubMedGoogle Scholar
  • 25 Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drug-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.  J Clin Epidemiol . 1993;  46 1331-1336
    CrossrefPubMedGoogle Scholar
  • 26 Maria V AJ, Victorino R MM. Development validation of a clinical scale for the diagnosis of drug-induced hepatitis.  Hepatology . 1997;  26 664-669
    CrossrefPubMedGoogle Scholar
  • 27 Aithal G P, Rawlins M D, Day C P. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions.  J Hepatol . 2000;  33 949-952
    CrossrefPubMedGoogle Scholar
  • 28 Knowles S R, Uetrecht J, Shear N H. Idiosyncratic drug reactions: the reactive metabolite syndromes.  Lancet . 2001;  356 1587-1591
    PubMedGoogle Scholar
  • 29 Dansette P M, Bonierbale F, Minoletti C. Drug-induced immunotoxicity.  Eur J Drug Metab Pharmacokinet . 1998;  23 443-451
    PubMedGoogle Scholar
  • 30 Bourdi M, Larrey D, Natal J. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450 1A2: a specific marker of dihydralazine-induced hepatitis.  J Clin Invest . 1990;  85 1967-1973
    CrossrefPubMedGoogle Scholar
  • 31 Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs ethanol, hormones cytokines.  J Hepatol . 1997;  26 43-53
    PubMedGoogle Scholar
  • 32 Krähenbühl S. Mitochondria: important target for drug toxicity?.  J Hepatol . 2001;  34 334-336
    CrossrefPubMedGoogle Scholar
  • 33 Larrey D, Letteron P, Foliot A. Effects of pregnancy on the toxicity metabolism of acetaminophen in mice.  J Pharmacol Exp Ther . 1986;  237 283-291
    PubMedGoogle Scholar
  • 34 Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy.  AIDS . 1998;  12 1256
    CrossrefPubMedGoogle Scholar
  • 35 Morgan M Y, Reshef R, Shah R R. Impaired oxidation of debrisoquine in patients with perhexiline liver injury.  Gut . 1984;  25 1057-1064
    CrossrefPubMedGoogle Scholar
  • 36 Larrey D, Pageaux G P. Genetic predisposition to drug-induced hepatotoxicity.  J Hepatol . 1997;  26 12-21
    CrossrefPubMedGoogle Scholar
  • 37 Shimada T, Tsumura F, Yamazaki H. Characterization of (±)-bufuralol hydroxylation activities in liver microsomes of Japanese Caucasian subjects genotyped for CYP2D6 Pharmacogenetics .  2001;  11 143-156
    PubMedGoogle Scholar
  • 38 Roddam P L, Rollinson S, Kane E. Poor metabolizers at the cytochrome P450 2D6 2C19 loci are at increased risk of developing adult acute leukaemia.  Pharmacogenetics . 2000;  10 605-615
    CrossrefPubMedGoogle Scholar
  • 39 Larrey D, Tinel M, Amouyal G. Genetically determined oxidation polymorphism drug hepatotoxicity. Study of 51 patients.  J Hepatol . 1989;  8 158-164
    PubMedGoogle Scholar
  • 40 Horsmans Y, Lannes B, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin hepatotoxicity caused by Atrium℗ a fixed combination preparation containing phenobarbital febarbamate and difebarbamate.  J Hepatol . 1994;  21 1075-1079
    CrossrefPubMedGoogle Scholar
  • 41 Xie H G, Stein M, Kim R B. Allelic genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.  Pharmacogenetics . 1999;  9 539-549
    CrossrefPubMedGoogle Scholar
  • 42 Kumashiro R, Kubota T, Iga T. Homozygous mutation of cytochrome P-450 2C19 is associated with troglitazone-induced hepatitis.  Hepatology . 2000;  32 197A
    PubMedGoogle Scholar
  • 43 Shear N H, Spielberg S P, Grant D M. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.  Ann Intern Med . 1986;  105 179-184
    PubMedGoogle Scholar
  • 44 Rieder M J, Shear N H, Kance A. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.  Clin Pharmacol Ther . 1991;  49 13-17
    PubMedGoogle Scholar
  • 45 Grant D M. Molecular genetics of the N-acetyltransferases.  Pharmacogenetics . 1993;  3 45-50
    PubMedGoogle Scholar
  • 46 Fretland A J, Leff M A, Doll M A, Hein D W. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms.  Pharmacogenetics . 2001;  11 207-215
    CrossrefPubMedGoogle Scholar
  • 47 Watson R GP, Olomu A, Clements D. A proposed mechanism for chlorpromazine jaundice-defective hepatic sulphoxidation combined with rapid hydroxylation.  J Hepatol . 1988;  7 72-78
    CrossrefPubMedGoogle Scholar
  • 48 Spielberg S P. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans.  Fed Proc . 1984;  43 2308-2313
    PubMedGoogle Scholar
  • 49 Larrey D, Berson A, Hebersetzer F. Genetic predisposition to drug hepatotoxicity. Role in hepatitis caused by amineptine a tricyclic antidepressant.  Hepatology . 1989;  10 168-173
    PubMedGoogle Scholar
  • 50 Bequemont L, Lecoeur S, Simon T. Glutathione S-transferase ;gu genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients.  Pharmacogenetics . 1997;  7 251-253
    PubMedGoogle Scholar
  • 51 De Sousa M, Pirmohamed M, Kitteringham N R. No association between tacrine transaminitis the glutathione transferase ;gu genotype in patients with Alzheimer's disease.  Pharmacogenetics . 1998;  8 353-355
    PubMedGoogle Scholar
  • 52 Berson A, Fréneaux E, Larrey D. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis.  J Hepatol . 1994;  20 336-342
    CrossrefPubMedGoogle Scholar
  • 53 Hautekeete M L, Horsmans Y, Van Waeyenberge C. HLA association of amoxicillin-clavulanate-induced hepatitis.  Gastroenterology . 1999;  117 1181-1186
    CrossrefPubMedGoogle Scholar
  • 54 Donohue J O, Oien K A, Underhill J. Co-amoxiclav jaundice: clinical histological features HLA class II association.  Gut . 2000;  47 717-720
    CrossrefPubMedGoogle Scholar